Bank of America Securities analyst Alec Stranahan maintained a Buy rating on HUTCHMED (HCM – Research Report) yesterday and set a price target of $29.00. The company’s shares closed yesterday at $13.50.
According to TipRanks, Stranahan is a 4-star analyst with an average return of 8.5% and a 54.00% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Krystal Biotech, and Novavax.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HUTCHMED with a $29.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $21.28 and a one-year low of $7.39. Currently, HUTCHMED has an average volume of 111.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.
Read More on HCM:
- Hutchmed announces ESLIM-01 trial met primary endpoint
- HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
- Hutchmed initiated with a Buy at Citi
- Hutchmed sees 2023 oncology/immunology revenues $450M-$550M
- Hutchmed reports 1H EPS 19c vs. (19c) last year
